Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 1.00 |
| ▸ | HTR2C | P28335 | 10/20 | 0.69 |
| ▸ | CNR1 | P21554 | 8/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198081 | 0.89 | HTR2A (0.80) | HTR2AHTR2C | |
| SCHEMBL6197646 | 0.89 | HTR2A (0.80) | HTR2AHTR2CCNR1CNR2 | |
| SCHEMBL6201643 | 0.88 | HTR2A (0.79) | HTR2AHTR2CCNR1CNR2 | |
| SCHEMBL6201055 | 0.88 | HTR2A (0.78) | HTR2AHTR2C | |
| SCHEMBL6199703 | 0.88 | HTR2A (0.78) | HTR2AHTR2C | |
| SCHEMBL6194881 | 0.87 | HTR2A (0.77) | HTR2AHTR2C | |
| SCHEMBL6200496 | 0.87 | HTR2A (0.77) | HTR2AHTR2C | |
| SCHEMBL6198959 | 0.87 | HTR2A (0.77) | HTR2AHTR2CCNR1 | |
| SCHEMBL6200786 | 0.87 | HTR2A (0.77) | HTR2AHTR2CCNR1 | |
| SCHEMBL6196740 | 0.86 | HTR2A (0.76) | HTR2AHTR2CCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509505-A2 | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2003062206-A2 | SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | claimed |
| US-20020156068-A1 | Anti-psychosis combination | ARENA PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | claimed |
| WO-2004028450-A2 | PROCESS OF MAKING PHENYLPYRAZOLES USEFUL AS SELECTIVE 5HT2A MODULATORS AND INTERMEDIATES THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20020156068-A1 | Anti-psychosis combination | ARENA PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002076464-A1 | ANTI-PSYCHOSIS COMBINATION | ARENA PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156068-A1 | Anti-psychosis combination | HTR2A, HTR2C, HTR5A | HTR2A 1/4885HTR2C 2/4885CNR1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.